Pliva

Last updated
Pliva d.o.o.
Company type Subsidiary
Industry Pharmaceutical industry
Founded1921;104 years ago (1921)
Headquarters Zagreb, Croatia
Key people
Mihael Furjan (CEO)
Products Generic drugs
Revenue$1.174 billion (2005)
$0.336 billion (2005)
Number of employees
1,700
Parent Teva Pharmaceuticals
Website www.pliva.com
Footnotes /references
[1]
Pliva headquarters in Zagreb Pliva Upravna zgrada.jpg
Pliva headquarters in Zagreb
Azithromycin, also known as Sumamed, is one of the world's best-selling antibiotics. Sumamed tablete 091208.jpg
Azithromycin, also known as Sumamed, is one of the world's best-selling antibiotics.

Pliva d.o.o. is a pharmaceutical company based in Zagreb, Croatia that primarily manufactures and sells generic drugs. It is a subsidiary of Teva Pharmaceuticals.

Pliva is one of the world's largest producers of generic Adderall.[ citation needed ]

History

The company was founded in 1921. [1]

A team of Pliva's researchers, Gabrijela Kobrehel, Gorjana Radobolja-Lazarevski and Zrinka Tamburašev led by Dr. Slobodan Đokić, discovered azithromycin in 1980. [2]

In June 2002, the company acquired Sidmak for $152.9 million. [3]

Also in June 2002, Zeljko Peric, the chief financial officer of the company, resigned. [4]

In May 2004, the company received approval from the Food and Drug Administration to sell trospium chloride. [5]

In June 2005, the company received approval to sell a generic version of erythropoietin in Croatia. [6]

In November 2005, the company received approval from the Food and Drug Administration to sell a generic version of Azithromycin, [7] Citalopram, [8] and Ondansetron. [9]

In October 2006, Barr Pharmaceuticals acquired Pliva. [10]

On December 23, 2008, Barr Pharmaceuticals was acquired by Teva Pharmaceuticals and the company became part of Teva Active Pharmaceutical Ingredients (TAPI). [11]

References

  1. 1 2 "Company Profile". Pliva.
  2. ↑ Mutak, Stjepan (2007). "Azalides from Azithromycin to New Azalide Derivatives". The Journal of Antibiotics. 60 (2): 85–122. doi:10.1038/ja.2007.10. ISSN   0021-8820.
  3. ↑ "PLIVA announces acquisition of US-based Sidmak" (Press release). Pliva. June 11, 2002.
  4. ↑ "PLIVA announces management changes" (Press release). Pliva. June 27, 2002.
  5. ↑ "PLIVA Announces FDA Approval of SANCTURA" (Press release). Pliva. May 31, 2004.
  6. ↑ "PLIVA Registers generic EPO in Croatia" (Press release). Pliva. June 21, 2005.
  7. ↑ "PLIVA Announces Approval for Azithromycin Tablets" (Press release). Pliva. November 15, 2005.
  8. ↑ "PLIVA Announces Approval for Citalopram Hydrobromide Tablets" (Press release). Pliva. November 3, 2005.
  9. ↑ "PLIVA Announces Approval for Ondansetron Hydrochloride ODT" (Press release). Pliva. November 21, 2005.
  10. ↑ "Barr Acquires PLIVA d.d." (Press release). Pliva. October 12, 2006.
  11. ↑ "TEVA COMPLETES ACQUISITION OF BARR" (Press release). Pliva. December 23, 2008.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.